Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33^rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystal’s presentation has been pre-recorded and is available on the Company’s website here.

Investors interested in arranging a virtual meeting with Cocrystal management should contact their Roth Capital Partners sales representative or LHA Investor Relations. Roth Conference information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
[email protected]

# # #

You May Also Be Interested In

• Media Advisory: Ottawa Community Housing to Break Ground on 159 New Affordable Homes in Lowertown
• 2026 Semiquincentennial Quarters Rolls & Bags – U.S. Constitution Available on August 26
• Pomona College to Provide Free Course Materials to All Students Through New Initiative